ATC Group: M01AX07 Benzydamine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M01AX07 in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M01 Antiinflammatory and antirheumatic products
3 M01A Antiinflammatory and antirheumatic products, non-steroids
4 M01AX Other antiinflammatory and antirheumatic agents, non-steroids
5 M01AX07 Benzydamine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code Route Amount Notes
ORAL Oral 0.15 g
RECTAL Rectal 0.15 g

Active ingredients in M01AX07

Active Ingredient

Benzydamine exerts an anti-inflammatory and analgesic action by stabilising the cellular membrane and inhibiting prostaglandin synthesis.

Related product monographs

Document Type Information Source  
 DIFFLAM Lozenge MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)

Medicines classified under this ATC code globally

Australia (AU)

Cyprus (CY)

Hong Kong (HK)

Ireland (IE)

Malta (MT)

New Zealand (NZ)

Singapore (SG)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.